The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA) living in Nigeria in routine care settings.
Phase:
PHASE4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
Aminu Kano Teaching Hospital Murtala Muhammed Specialist Hospital National Institute of Neurological Disorders and Stroke (NINDS)